Home › Research › Clinical trials
Vortioxetine Treatment for Depression in Alzheimer's Disease: A Randomized, Double-blind, Placebo-controlled Study
Hye Won Jeong, Kyung Hee Yoon, Chang Hyun Lee, Yoo Sun Moon, Do Hoon Kim. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2022-05-31
Topic: Drug trials: efficacy and safety
Plain-language summary
There was no statistically significant difference between the two groups in terms of depressive symptoms, cognitive functions, and ADL. Further, the percentage of adverse events and drug discontinuation between the vortioxetine and placebo groups was similar. Our results suggest that vortioxetine might not be effective in reducing depressive symptoms or cognitive impairment in AD patients with depression. However, general drug tolerance and patient safety were similar to those of placebo. Thus, additional studies are needed to replicate the effectiveness and tolerability of vortioxetine in AD patients with depression.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jeong, H. W., Yoon, K. H., Lee, C. H., Moon, Y. S., & Kim, D. H. (2022). Vortioxetine Treatment for Depression in Alzheimer's Disease: A Randomized, Double-blind, Placebo-controlled Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. https://doi.org/10.9758/cpn.2022.20.2.311
Vancouver
Jeong HW, Yoon KH, Lee CH, Moon YS, Kim DH. Vortioxetine Treatment for Depression in Alzheimer's Disease: A Randomized, Double-blind, Placebo-controlled Study. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2022. doi:10.9758/cpn.2022.20.2.311. PMID: 35466102.
BibTeX
@article{jeong2022-35466102,
author = {Jeong, Hye Won and Yoon, Kyung Hee and Lee, Chang Hyun and Moon, Yoo Sun and Kim, Do Hoon},
title = {{Vortioxetine Treatment for Depression in Alzheimer's Disease: A Randomized, Double-blind, Placebo-controlled Study}},
journal = {Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology},
year = {2022},
doi = {10.9758/cpn.2022.20.2.311},
pmid = {35466102},
url = {https://doi.org/10.9758/cpn.2022.20.2.311}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There was no statistically significant difference between the two groups in terms of depressive symptoms, cognitive functions, and ADL.
- Further, the percentage of adverse events and drug discontinuation between the vortioxetine and placebo groups was similar.
- Our results suggest that vortioxetine might not be effective in reducing depressive symptoms or cognitive impairment in AD patients with depression.
- However, general drug tolerance and patient safety were similar to those of placebo.
- Thus, additional studies are needed to replicate the effectiveness and tolerability of vortioxetine in AD patients with depression.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Participants100
- Evidence strengthLow
How this study scored 54/100
Published in a peer-reviewed journal. Scored zero for study design and effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 30 of the 56 points we could judge it on, which is 54 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 100 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35466102) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 30 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 30 of the 56 points we could judge it on is 54 out of 100. |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “late-life-depression”
139 studies in the library carry the topic tag “late-life-depression”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 139 tagged studies.